<DOC>
	<DOCNO>NCT02755987</DOCNO>
	<brief_summary>This expand access study ANG1005 treatment two individual patient Protocol ANG1005-CLN-03 WHO Grade III Anaplastic Astrocytoma WHO Grade III Anaplastic Oligodendroglioma one individual patient Protocol ANG1005-CLN-04 Recurrent Brain Metastases Leptomeningeal Carcinomatosis .</brief_summary>
	<brief_title>Expanded Access ANG1005 Individual Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Astrocytoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Oligodendroglioma</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Meningeal Carcinomatosis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Neurologically stable 2 . Karnofsky performance status ( KPS ) ≥ 80 3 . Adequate laboratory result 1 . Radiotherapy within 3 month . 2 . Evidence significant intracranial hemorrhage 3 . NCI Common Toxicity Criteria Adverse Effects ( CTCAE ) v4.0 Grade ≥ 2 neuropathy 4 . Inadequate bone marrow reserve 5 . Any evidence severe uncontrolled disease</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>